Payment overview · 2025
General Payments
$604.96
2 reported records · 1 companies
Healthcare provider profile · identity verified
Heather M Morgan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · OMAHA, NE · NPI 1922013531
Verified facts
What the public records show
CMS Open Payments records show Heather M Morgan, M.D. received $604.96 in general payments during 2025 across 2 reported records.
Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $604.96 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $600.00 | 1 |
| Food and Beverage | $4.96 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $4.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 539 | 181 |
| Atorvastatin Calcium | Atorvastatin Calcium | 535 | 207 |
| Sertraline Hcl | Sertraline Hcl | 451 | 148 |
| Omeprazole | Omeprazole | 357 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 297 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 250 | 100 |
| Furosemide | Furosemide | 239 | 77 |
| Losartan Potassium | Losartan Potassium | 238 | 97 |
| Gabapentin | Gabapentin | 220 | 85 |
| Potassium Chloride | Potassium Chloride | 214 | 91 |
| Lisinopril | Lisinopril | 199 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 64 |
| Trazodone Hcl | Trazodone Hcl | 199 | 69 |
| Memantine Hcl | Memantine Hcl | 193 | 34 |
| Mirtazapine | Mirtazapine | 186 | 60 |
| Eliquis | Apixaban | 182 | 49 |
| Alendronate Sodium | Alendronate Sodium | 175 | 73 |
| Donepezil Hcl | Donepezil Hcl | 135 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 48 |
| Simvastatin | Simvastatin | 119 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 41 |
| Montelukast Sodium | Montelukast Sodium | 105 | 28 |
| Tramadol Hcl | Tramadol Hcl | 102 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 34 |
| Metformin Hcl | Metformin Hcl | 82 | 44 |
| Allopurinol | Allopurinol | 81 | 25 |
| Carvedilol | Carvedilol | 76 | 30 |
| Atenolol | Atenolol | 74 | 20 |
| Myrbetriq | Mirabegron | 73 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 22 |
| Famotidine | Famotidine | 61 | 23 |
| Trulicity | Dulaglutide | 58 | 15 |
| Metformin Hcl Er | Metformin Hcl | 54 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 17 |
| Restasis | Cyclosporine | 46 | suppressed |
| Alprazolam | Alprazolam | 44 | 20 |
| Ozempic | Semaglutide | 44 | 15 |
| Meloxicam | Meloxicam | 43 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 13 |
| Bupropion Xl | Bupropion Hcl | 40 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 15 |
| Warfarin Sodium | Warfarin Sodium | 40 | 11 |
| Prednisone | Prednisone | 36 | 19 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | 11 |
| Pregabalin | Pregabalin | 35 | 13 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 19 |
| Buspirone Hcl | Buspirone Hcl | 30 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Nystatin | Nystatin | 29 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | 15 |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Lorazepam | Lorazepam | 25 | 11 |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Loperamide | Loperamide Hcl | 24 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Finasteride | Finasteride | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | 14 |
| Synthroid | Levothyroxine Sodium | 22 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $604.96 · 2 records | Lilly USA, LLC | KISUNLA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error